Serina Therapeutics (SER) Proxy filing summary

Executive summary

• Annual Meeting scheduled for December 13, 2024, will be held virtually with no in-person attendance.

• Key items for shareholder vote include director elections, auditor ratification, and an amendment to the 2024 Equity Incentive Plan.

• The company completed a merger and rebranding in March 2024, transitioning from AgeX Therapeutics, Inc. to Serina Therapeutics, Inc.

Voting matters and shareholder proposals

• Election of three Class I directors for terms expiring at the 2027 Annual Meeting.

• Ratification of Frazier & Deeter, LLC as independent auditors for fiscal year ending December 31, 2024.

• Approval of an amendment to the 2024 Equity Incentive Plan to increase share reserve to 2,675,000, add an evergreen provision, and modify share reversion provisions.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board is divided into three classes with staggered three-year terms; current nominees are all incumbents.

• Board members bring expertise in biotechnology, finance, and venture capital.

• Majority of directors are independent per NYSE American standards.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.

• Code of Ethics applies to all directors and executive officers.